Physician
Internal Medicine
Dr. Philippe Szapary, MD
|
|
Give Review
Philippe Szapary practices Internal Medicine. He graduated from University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine has a rank of 10 in research and a 19 in primary care He has 1 awards "CMS Meaningful Use Stage 1 Certification". Philippe Szapary is also a published doctor. He has 59 publication published. The most recent publication is: Body mass and hypertension in women. Philippe Szapary accepts Medicare payments and is listed with Medicare.gov.
Publications
- Ustekinumab in adolescent patients age 12 to 17Â years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study.
- Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint.
- Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
- Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis.
- Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
- Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5?years in the PHOENIX 1 study.
- The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
- A randomized trial of the effects of an almond-enriched, hypocaloric diet in the treatment of obesity.
- Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives - an update.
- Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis.
- Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled...
- Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from poole...
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
- An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
- Body mass and hypertension in women.
- Physicians recommendations for and personal use of low-fat and low-carbohydrate diets.
- Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials.
- Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patient...
- Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature.
- Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
- Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following...
- Horse chestnut:a multidisciplinary clinical review.
- Shark cartilage monograph: a clinical decision support tool.
- Alfalfa (Medicago sativa L.):a clinical decision support tool.
- Physicians' personal intake and prescription of weight loss products: are we practicing what we preach?
- Therapeutic applications of fenugreek.
- An evidence-based systemic review Echinacea E. angustifolia DC, E. pallida, E. purpurea by the Natural Standard Research Collaboration.
- Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration.
- Evidence-based systematic review of saw palmetto by the Natural Standard Research Collaboration.
- Marigold (Calendula officinalis L.): an evidence-based systematic review by the Natural Standard Research Collaboration.
- CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans.
- Flax and flaxseed oil (Linum usitatissimum): a review by the Natural Standard Research Collaboration.
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo...
- Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
- Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a rand...
- Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
- Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
- Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
- Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment ...
- Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.
- Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults.
- Antidiabetic action of bezafibrate in a large observational database.
- Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial.
- The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
- Flaxseed reduces plasma cholesterol levels in hypercholesterolemic mouse models.
- Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.
- Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
- Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
- The triglyceride-high-density lipoprotein axis: an important target of therapy?
- The new definition of myocardial infarction.
- Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.
- Flaxseed and cardiovascular risk.
- Physical activity and its effects on lipids.
- Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.
- A randomized trial of a low-carbohydrate diet for obesity.
Schools
University of Chicago
University Ca Sf School Of Med
Doctors Specialties
- Internal Medicine
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Card PPO
- Capital Blue Cross
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health America PPO
- Coventry Health Care of Delaware PPO
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Community Blue PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- Medicare MCR
- MultiPlan PPO
- QualCare HMO
- QualCare PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University Pennsylvania School of Medicine -
UCSF -
University of Chicago Pritzker School of Medicine
Hospital
-
Hospital of the University of Pennsylvania
Drug Facts
| NPI NUMBER | 1003009085 | |
| NPPES Provider LastName | SZAPARY | |
| NPPES Provider FirstName | PHILIPPE | |
| NPPES Provider ZIPCode | 191045127 | |
| NPPES Provider State | PA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 120.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003009085 |
| Last Name Of The Provider | SZAPARY |
| First Name Of The Provider | PHILIPPE |
| View All |
Similar Doctors
|
|
Colleen M. Thom |
|
|
Dr. Neil J. Mallis, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Inessa G. Biniaurishvili, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Wheeler, MD |
|
|
Dr. Andrew C. Peters, MD |
|
|
Dr. Karl T. Benedict III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kelsey T. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mrinalini Sarkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aaloke Mody, MD |
|
|
Dr. Tiffanie K. Jones, MD |
|
|
Dr. William R. Petricone Jr., MD |
|
|
Dr. Nicholas M. Devito, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aleksandr Shpigel, MD
This Doctor is OpenDoctor Recommended.
|